GLR2037 / Gan & Lee Pharma - LARVOL DELTA

Discovery of GLR203701, a highly potent AR PROTAC with favorable PK profile and optimized tissue distribution characteristic (AACR 2025) - "Phase 1 dose escalation trial showed systemic exposure of ARV-766 reached maximum at 320 mg/day in humans. Taking the high exposure level and good bioavailability, GLR203701 is expected to generate a board therapeutic window. These preclinical data support the clinical development of GLR203701 for the treatment of mCRPC."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer (clinicaltrials.gov) - P1 | N=65 | Not yet recruiting | Sponsor: Gan & Lee Pharmaceuticals.

New P1 trial • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor